Mr. Culverwell has served as a director of Quoin Inc. since April 2021 and as a director of Quoin Ltd. since October 28, 2021. He is also currently serving as the Chief Executive Officer and Chairman of the Board of Directors of HOX Therapeutics. He serves as a director and Audit Committee Chairman of TC BioPharm (Holdings) plc (Nasdaq: TCBP) and he serves as a director, Audit Committee Chairman, and member of the Compensation Committee of SafeGuard Biosystems. In 2005, Mr. Culverwell founded Sudbrook Associates, which provided strategic advice and fundraising services for life science companies. Previously, Mr. Culverwell was Senior Vice President and Global Coordinator Healthcare Research at Merrill Lynch. He also served as Director of Healthcare Equity Research at ABN Amro Bank N.V., director and Audit Committee Chairman of Amryt Pharma PLC (Nasdaq: AMYT), and director and Audit Committee Chairman of Innocoll AG. He received an MSc with honors from the University of Aberdeen.